Active role of the immune system in metabolic dysfunction-associated steatotic liver disease

被引:2
作者
Mori, Taizo [1 ]
Yoshio, Sachiyo [1 ]
Kakazu, Eiji [1 ]
Kanto, Tatsuya [1 ]
机构
[1] Natl Ctr Global Hlth & Med, Res Ctr Hepatitis & Immunol, Dept Liver Dis, Chiba, Japan
来源
GASTROENTEROLOGY REPORT | 2024年 / 12卷
关键词
MASLD; MASH; innate immunity; liver fibrosis; inflammatory cytokine; KILLER T-CELLS; NEUTROPHIL EXTRACELLULAR TRAPS; NONALCOHOLIC STEATOHEPATITIS; DENDRITIC CELLS; NK CELLS; TRANSCRIPTIONAL REGULATION; HEPATIC STEATOSIS; OBETICHOLIC ACID; CONTROLLED-TRIAL; INFLAMMATION;
D O I
10.1093/gastro/goae089
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease, recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is a complex multifactorial disease that progresses from steatohepatitis (MASH) to liver cirrhosis and liver cancer. Recent research has revealed that crosstalk between innate immune cells and hepatic parenchymal and non-parenchymal cells is involved in the pathogenesis of liver disease in MASLD/MASH. Of particular importance, novel inflammatory mechanisms, including macrophage diversity, neutrophil NETosis, B-cell biology, auto-reactive T cells, unconventional T cells, and dendritic cell-T cell interactions, are considered key drivers for disease progression. These mechanisms and factors are potential targets for the therapeutic intervention of MASLD/MASH. In this review, we focus on recent discoveries related to liver inflammation and discuss the role of innate immune cell subsets in MASLD/MASH.
引用
收藏
页数:11
相关论文
共 159 条
  • [1] Natural Killer Cells: Development, Maturation, and Clinical Utilization
    Abel, Alex M.
    Yang, Chao
    Thakar, Monica S.
    Malarkannan, Subramaniam
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [2] The ontogenetic path of human dendritic cells
    Amon, Lukas
    Lehmann, Christian H. K.
    Heger, Lukas
    Heidkamp, Gordon F.
    Dudziak, Diana
    [J]. MOLECULAR IMMUNOLOGY, 2020, 120 : 122 - 129
  • [3] Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
    Angulo, P
    Keach, JC
    Batts, KP
    Lindor, KD
    [J]. HEPATOLOGY, 1999, 30 (06) : 1356 - 1362
  • [4] Research in Brief
    Baker, Holly
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06): : 508 - 508
  • [5] Innate Immunity and Inflammation in NAFLD/NASH
    Arrese, Marco
    Cabrera, Daniel
    Kalergis, Alexis M.
    Feldstein, Ariel E.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) : 1294 - 1303
  • [6] Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury
    Baeck, Christer
    Wehr, Alexander
    Karlmark, Karlin Raja
    Heymann, Felix
    Vucur, Mihael
    Gassler, Nikolaus
    Huss, Sebastian
    Klussmann, Sven
    Eulberg, Dirk
    Luedde, Tom
    Trautwein, Christian
    Tacke, Frank
    [J]. GUT, 2012, 61 (03) : 416 - 426
  • [7] Galectin-3 critically mediates the hepatoprotection conferred by M2-like macrophages in ACLF by inhibiting pyroptosis but not necroptosis signalling
    Bai, Li
    Lu, Wang
    Tang, Shan
    Tang, Huixin
    Xu, Manman
    Liang, Chen
    Zheng, Sujun
    Liu, Shuang
    Kong, Ming
    Duan, Zhongping
    Chen, Yu
    [J]. CELL DEATH & DISEASE, 2022, 13 (09)
  • [8] Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
    Barranco-Fragoso, Beatriz
    Pal, Shreya C.
    Diaz-Orozco, Luis E.
    Dorantes-Heredia, Rita
    Qi, Xingshun
    Mendez-Sanchez, Nahum
    [J]. MEDICAL SCIENCE MONITOR, 2022, 28
  • [9] The Emerging Role of B Cells in the Pathogenesis of NAFLD
    Barrow, Fanta
    Khan, Saad
    Wang, Haiguang
    Revelo, Xavier S.
    [J]. HEPATOLOGY, 2021, 74 (04) : 2277 - 2286
  • [10] Barrow F, 2021, HEPATOLOGY, V74, P704, DOI [10.1002/hep.31755/suppinfo, 10.1002/hep.31755]